echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > AstraZeneia's new crown vaccine program is recruiting 50,000 volunteers worldwide, with Phase III clinical opening in the United States.

    AstraZeneia's new crown vaccine program is recruiting 50,000 volunteers worldwide, with Phase III clinical opening in the United States.

    • Last Update: 2020-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On the evening of September 1, AstraZenecom announced that its Phase III clinical trial of the COVID-19 vaccine AZD1222 would be expanded to the United States, the third new crown candidate to be tested in the United States.
    the project, called D8110C00001, is funded by the U.S. Biomedical Advanced Research and Development Administration (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
    now, AstraZeneta is recruiting nearly 30,000 adults aged 18 and over to conduct trials that include both healthy people and people with stable underlying conditions, as well as people from different ethnic groups and places.
    , the volunteers also include people living with HIV and those at higher risk of new coronavirus infection.
    the clinical trial, volunteers were divided into vaccine and control groups, each with two injections, four weeks apart.
    said it plans to recruit more than 50,000 volunteers worldwide to take part in the trial.
    addition to the 30,000 volunteers in the United States, the company will also launch volunteer recruitment in Latin America, Asia, Europe and Africa.
    as part of its plan, AstraZeneta has reached supply agreements with Russia, South Korea, Japan, China, Latin America and Brazil to guarantee a global supply of 3 billion doses of vaccines.
    June, AstraZenecom announced plans to produce 2 billion doses of the new crown vaccine, of which 400 million were distributed to the United States and the United Kingdom and 1 billion to low- and middle-income countries.
    AZD1222 was jointly developed by AstraZeneta and Oxford University.
    The results of previous trials published in The Lancet medical journal showed that the vaccine did not produce any serious side effects in 1,077 volunteers in early-stage clinical trials, meaning the vaccine was safe;
    Lin Yiling Source: EY !-- content presentation ends -- !-- to determine whether the login ends.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.